Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)

BACKGROUND. Angiosarcomas account for <2% of all soft tissue sarcomas. This subtype is one of the most aggressive forms of soft tissue sarcoma. The prognosis for angiosarcoma patients in the advanced phase remains poor with current cytotoxic agents (progression-free survival [PFS] time of ∼4 mont...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ray-Coquard, Isabelle, Italiano, Antoine, Bompas, Emmanuelle, Le Cesne, Axel, Robin, Yves-Marie, Chevreau, Christine, Bay, Jacques-Olivier, Bousquet, Guilhem, Piperno-Neumann, Sophie, Isambert, Nicolas, Lemaitre, Laurent, Fournier, Charles, Gauthier, Eric, Collard, Olivier, Cupissol, Didier, Clisant, Stéphanie, Blay, Jean-Yves, Penel, Nicolas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2012
Gaiak:
Sarcomas
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3286175/
https://ncbi.nlm.nih.gov/pubmed/22285963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0237
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak